Alpha-L-iduronidase (IDUA) is a critical lysosomal enzyme responsible for the degradation of unsulfated alpha-L-iduronic acid residues in dermatan sulfate and heparan sulfate. Mutations in the IDUA gene lead to Mucopolysaccharidosis Type I (MPS I), a severe lysosomal storage disorder encompassing Hurler, Hurler-Scheie, and Scheie syndromes. Modern therapeutic strategies are shifting from standard Enzyme Replacement Therapy (ERT) to brain-penetrant enzyme fusions, gene therapies (AAV and lentiviral HSCs), and mRNA-based therapeutics. Developing these advanced modalities requires highly characterized recombinant proteins and cell-based validation models that preserve native post-translational modifications, particularly Mannose-6-Phosphate (M6P) glycosylation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IDUA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IDUA Recombinant Protein HEK293 expressed (native glycosylation), High purity (>95%), Endotoxin controlled, Sequence Verified. |
View IDUA Products |
| Gene Delivery | IDUA Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View IDUA Products |
| Benchmark Ab | Anti-IDUA Recombinant Antibody Sequence derived from clinical benchmarks; ideal positive control for binding and internalization assays. |
View IDUA Products |
| Validator | IDUA siRNA Set Target-specific knockdown pool for functional assay specificity controls. |
View IDUA Products |
| Related Target A | IGF2R (M6PR) Cation-independent mannose-6-phosphate receptor; key mediator for lysosomal targeting and cellular uptake of IDUA. |
View IGF2R Products |
| Related Target B | IDS Iduronate 2-sulfatase; related lysosomal enzyme mutated in MPS II (Hunter Syndrome), essential for specificity and cross-reactivity panels. |
View IDS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| M6P-dependent cellular internalization validation | HEK293 host expression ensures native human glycosylation and M6P modification for physiological receptor binding. |
| Blood-Brain Barrier (BBB) transport screening | High-purity soluble IDUA proteins available for conjugation or fusion validation with transferrin or insulin receptor antibodies. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks in cellular uptake and enzyme activity models. |
Live IDUA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for IDUA-related disorders is undergoing a technological revolution. While first-generation ERT (Laronidase/Aldurazyme) remains the standard of care, its inability to cross the blood-brain barrier limits efficacy against progressive neurodegeneration in Hurler syndrome. Consequently, the next wave of drug discovery focuses on BBB-crossing enzyme fusions (e.g., anti-TfR-IDUA or anti-LDLR-IDUA fusions) and ex vivo lentiviral gene therapies (such as OTL-203) designed to cross-correct CNS cells. Additionally, in vivo AAV-mediated gene therapies targeting the liver or directly into the CSF are in active clinical development to establish sustained, long-term enzyme expression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| BBB-Penetrant Fusion Proteins | JCR Pharmaceuticals, Denali Therapeutics | MPS I (Hurler Syndrome with CNS involvement) | Internalization Assay & M6PR Binding (Requires HEK293-expressed IDUA and IGF2R) |
| Gene Therapy (HSC-Lentivirus) | Orchard Therapeutics (OTL-203) | Severe Mucopolysaccharidosis Type I | Transduction & Expression Validation (Requires IDUA Lentivirus and custom ORF constructs) |
| Gene Therapy (AAV) | REGENXBIO (RGX-111) | MPS I (CNS manifestations) | In vivo biodistribution mimicry & neutralizing antibody screening (Requires high-purity IDUA protein) |